Adherence to antiretroviral therapy is essential to treatment success for individuals living with HIV/AIDS. Despite the wealth of studies in examining antiretroviral non-adherence, few have distinguished between intentional and unintentional non-adherence. The present study attempted to identify factors associated with adherence, intentional non-adherence, and unintentional non-adherence among HIV' individuals using a longitudinal design. Dietary instructions and medication schedule were also included to measure the subtleties of antiretroviral adherence. One hundred and two HIV' patients who were under antiretroviral therapy were recruited in an outpatient clinic in Hong Kong at baseline with six months follow-up. Using the conventional adherence rate, only 12 (11.8%) of participants reported having missed/ altered medication in the past four days. However, using a more comprehensive assessment, only 27 (26.5%) participants were classified as adherers. Results showed that, adherers were significantly older and had higher adherence self-efficacy than those who were unintentional or intentional non-adherers. Participants classified as unintentional non-adherers had longer length of diagnosis and started medication longer than adherers and intentional non-adherers. Participants classified as intentional non-adherers had worse mental health, higher level of self-stigma, and reported higher score in avoidant coping than adherers and unintentional non-adherers. They also scored higher in physical symptoms than adherers. Findings highlight the importance of a reliable, comprehensive measurement for adherence and extend on previous adherence literature that intentional and unintentional non-adherence are separate entities and are associated with different factors. Future research should understand the intentions behind non-adherence and this would serve as an important guide in the development of interventions aimed at improving antiretroviral adherence for HIV' patients.
Introduction

Antiretroviral therapy in HIV
The advent of antiretroviral therapy has greatly transformed the lives of persons living with HIV/ AIDS (PLWA). While antiretroviral therapy has resulted in remarkable decrease in AIDS-related morbidity and mortality (Garcia de Olalla et al., 2002; Jain et al., 2003; Lohse, Hansen, Gerstoft, & Obel, 2007; McNaghten, Hanson, Jones, Dworkin, & Ward, 1999) , an extremely high level of adherence (e.g. B95%) is required to guarantee treatment effectiveness due to rapid replication and mutation rate of HIV (Bangsberg et al., 2000; Montaner et al., 1998; Paterson et al., 2000) .
Factors associated with antiretroviral adherence
As adherence to antiretroviral medication is essential for clinical effectiveness, research in this area has associated with non-adherence, adherence to antiretroviral therapy remains suboptimal. The prevalence of non-adherence ranges from less than 80% to as low as 3%, depending on different operational definitions, studying populations, and methodologies (Walsh, Dalton, & Gazzard, 1998) .
Intentionality of antiretroviral non-adherence
One reason for less than optimal adherence might be the failure of studies in distinguishing between intentional and unintentional non-adherence. It is suggested that, intentional and unintentional nonadherence are separate entities and they occur for different reasons (Lehane & McCarthy, 2007b; Wroe, 2002) . Studies in various health conditions showed that concerns about side effects, stigma associated with medications, and perceiving the medication as unnecessary were associated with intentional nonadherence, whereas cognitive impairments, access to medications, interruptions in one's patterns of medication intake, and forgetfulness were associated with unintentional non-adherence (Ayalon, Arean, & Alvidrez, 2005; Johnson, Williams, & Marshall, 1999; Lehane & McCarthy, 2007a; Remien et al., 2003; Wroe, 2002) . One study in HIV/AIDS also highlighted that severe symptoms were associated with intentional non-adherence (Heath, Singer, O'Shaughnessy, Montaner, & Hogg, 2002) . Despite this, intentionality of non-adherence in HIV/AIDS has received very little attention.
Measuring non-adherence
Medication adherence is a complex concept that requires detailed, sophisticated assessment (Hill, Kendall, & Fernandez, 2003; Hugen et al., 2002; Samet, Sullivan, Traphagen, & Ickovics, 2001; Sankar, Nevedal, Neufeld, & Luborsky, 2007; Wilson, Tchetgen, & Spiegelman, 2001 ). However, majority of studies have focused only on the administration of prescribed dose, and have classified participants into adherers or non-adherers based on whether they take a certain percentage of prescribed medication during a time period (Catz, Kelly, Bogart, Benotsch, & McAuliffe, 2000; Chesney et al., 2000; Garcia de Olalla et al., 2002; Knobel et al., 2002) . Despite the fact that adherence to instructions regarding dietary requirements, amount and schedule of medications, and lifestyle habits substantially influence the efficacy of medication regimens (Altice & Friedland, 1998; Murphy, Marelich, Hoffman, & Steers, 2004; Stone et al., 2001 ), they have not been well incorporated into the measurement of medication adherence. One recent study employed a more extensive measurement by including more aspects of adherence and found this to be valid and reliable (Reynolds et al., 2007) . Ideally, these perspectives should be assessed along with the amount of prescribed medications taken.
The present study The present study aimed to identify factors associated with adherence, intentional non-adherence, and unintentional non-adherence among PLWA in Hong Kong using a more extensive measurement of adherence. Comprehensive, feasible and accurate measures of adherence are important to identify patients who do not adhere to medication for various reasons and to design and evaluate interventions to improve medication adherence among PLWA.
Methods
Procedure
Participants were recruited at the AIDS outpatient clinic in Hong Kong. Potential participants were identified by nurses and were approached by a trained interviewer. Inclusion criteria included: (1) aged 18 years or older; (2) having been tested HIVpositive for at least one month; and (3) being currently on antiretroviral medication. Interested participants were invited for a structured interview. Based on their dates of next medication appointment, participants were followed up approximately six months after the initial interview. Upon completion of each interview, participants were given a supermarket voucher of HK$50 (approximately US$6.40) as a token of appreciation. The study has been approved by the local Institutional Review Board prior to commencement.
Measures
The following measures were administered at Time 1:
Adherence self-efficacy Adherence self-efficacy was measured by a single item from the AIDS Clinical Trial Group (ACTG) adherence measure (Chesney et al., 2000) . Item was measured on a five-point Likert Scale ranging from 0 to 4, with higher scores showing higher self-efficacy. In the present study, participants who scored four were classified as reporting high level of self-efficacy.
Self-stigma A self-stigma scale was used to assess the level of perceived stigma of participants (Mak et al., 2007) . It is a 22-item scale which measures three dimensions of self-stigma (affective, behavioural, and cognitive).
Responses are rated on a six-point Likert scale ranging from 1 to 6, with higher scores indicating greater level of self-stigma. The Cronbach's alpha of the scale was 0.87 in the present study.
Coping
Coping was measured by the Brief COPE, a 28-item scale that measures 14 types of cognitive or behavioural coping processes (Carver, 1997; Carver, Scheier, & Weintraub, 1989) . Items were measured on a four-point Likert Scale ranging from 1 to 4, with higher score indicating greater use of the coping strategies. In the present study, items were grouped into three subscales: problem-focused, emotion-focused, and avoidant coping (Carver et al., 1989) . The Cronbach's alphas of the three subscales were 0.71, 0.73, and 0.81, in the present study.
Mental health
The 38-item Mental Health Inventory (MHI) was used to assess the level of mental health of participants (Veit & Ware, 1983) . Items are rated on a sixitem scale ranging from 1 to 6, with higher score indicating better mental health. The Cronbach's alpha of the scale was 0.82 in the present study.
Physical symptoms
Physical symptoms were assessed by a 20-item checklist developed by Folkman and colleagues (Folkman, Chesney, Collette, Boccellari, & Cooke, 1996) . A fivepoint Likert scale ranging from 0 to 4 was provided for each item, with higher scores indicating more severe physical symptoms. The Cronbach's alpha of the scale was 0.81 in the present study.
The following measure was administered at Time 2.
Medication adherence
The ACTG adherence measure (Chesney et al., 2000) was adopted and modified for the purposes of the present study. Participants were asked to list the details of medications they were currently prescribed and the time and dosage of medications they have taken in the past four days. Additional questions were asked to participants on how well they followed the dietary instructions, whether they always remembered to take their medication, and whether they skipped medication over the past weekend. Participants were also asked to rate their frequency of missing medication and frequency of taking doses two hours earlier or later. Participants who reported ever skipping or alternating medications were presented with a list of reasons why people may miss taking medications and were asked to choose the reason(s) that applied to them.
Results
Participants
Out of the 126 participants who have completed the initial interview, 102 participants (81.0%) completed the follow-up interview. The mean lapse between the initial and follow-up interview was 6.89 months (SD 01.88). Majority of the participants were male (87.3%). Their mean age was 41.9 years (SD 010.04). More than two-thirds of them (70.0%) were in advanced AIDS stage and they have been diagnosed for an average of 5.18 years (SD 03.24). The mean reported daily pill count was 7.09 (SD 03.52).
To assess whether the participants who were retained in the follow-up differed from those who are lost, Chi-square tests and independent t-tests were conducted on major demographic and medical factors measured at Time 1. Results showed no significant difference on major demographic and medical variables, with the exception that participants who were retained had slightly lower CD4 count (338.05 cells/mm 3 ) than those who were lost (436.04 cells/mm 3 ). The demographic and medical information of participants are shown in Table 1 .
Rate of medication adherence
The conventional adherence rate, calculated by the number of missing doses divided by number of doses prescribed, was very high, with only 12 participants (11.8%) reported having missed doses in the past four days. However, when asked whether they always remembered to take their medication, only 74 (72.5%) reported 'always' and an additional 10 (9.8%) reported 'most of the time'. When asked how often they missed taking their medication, only 34 (33.3%) reported 'never' and 43 (42.2%) reported 'seldom'. Also, when asked how often they take medications two hours earlier or later, only 28 (27.5%) reported 'never' and 34 (33.3%) reported 'seldom'. Finally, when asked when was the last time they missed medication, eight (7.8%) reported that it was within the past week, 11 (10.8%) 1Á2 weeks ago, 11 (10.8%) 2Á4 weeks ago, 12 (11.8%) 1Á3 months ago, 16 (15.7%) more than three months ago, and 40 (39.2%) reported that they never skip or miss medication.
To account for dietary instructions and alternating doses in medication adherence, participants who reported remembering taking medication most of the AIDS Care 787 time; and following the time and dose of medications and their dietary instructions most of the time in the past four days; not having skipped medication over the past weekend; and rarely missing or alternating doses were classified as adherers. Participants who were not classified as adherers were further divided as intentional non-adherers or unintentional non-adherers based on their reason of missing medications (refer to the following section). Using the above criteria, only 27 (26.5%) participants were classified as adherers and 75 (73.5%) were classified as non-adherers.
Factor analysis of reason for medication non-adherence To determine the factor structure of medication nonadherence, exploratory factor analysis was conducted on the reasons for missing medication. Results from exploratory factor analysis, using the maximum likelihood estimation method, produced a two-factor solution (Table 2) . Specifically, feeling good for not taking pills, avoiding side effects, feeling difficult for taking pills at specific time, and having too many pills to take were loaded on factor 1, while being away from home, out of pills, being busy with other things, forgetting, having slept, and not feeling well were loaded on factor 2.
Based on the result of factor analysis, participants who have chosen higher proportion of reasons listed in factor 1 were classified as intentional non-adherers, while those who have chosen higher proportion of reasons listed in factor 2 were classified as unintentional non-adherers. Using the above criteria, 53 (52.0%) participants were classified as unintentional non-adherers, while 21 (20.6%) participants were classified as intentional non-adherers.
Difference in demographic and medical status between groups
Results from one-way ANOVA revealed significant group difference on age, F(1,100) 04.94, pB0.01. Post hoc analysis showed that adherers were significantly older at baseline. In addition, results of Kruskal-Wallis tests indicated significant group differences on time since starting medication, H(2) 09.06, p B0.01, and length of diagnosis, H(2) 011.72, p B0.05. Follow-up Mann-Whitney U tests showed that unintentional non-adherers had longer length of diagnosis and have started medication longer. The group difference in demographic and medical status is presented in Table 3 .
Difference in psychosocial variables between groups
Result from one-way ANOVA showed significant group difference on self-stigma, F(1,100) 07.58, pB0.001, avoidant coping, F(1,100) 05.09, p B0.01, physical symptoms, F (1,100) 03.08, p B0.05, and mental health, F(1,100) 06.25, p B0.001. Post hoc analyses revealed that intentional non-adherers had significantly higher level of stigma and avoidant coping, and worse mental health than unintentional non-adherers and adherers at baseline. They also reported significantly more severe physical symptoms than adherers. In addition, results from chi-square test showed a significant group difference in adherence self-efficacy, x 2 (2) 019.08, pB0.001. Follow-up analyses indicated that while all adherers reported high level of adherence self-efficacy, only slightly more than half of unintentional non-adherers (55%) and intentional non-adherers (52.5%) showed high level of adherence self-efficacy. The group difference in psychosocial variables is presented in Table 4 .
Discussion
Factors associated with adherence
The present study aimed to examine factors associated with antiretroviral adherence, intentional nonadherence, and unintentional non-adherence among PLWA in Hong Kong. Participants who were older at baseline tended to report excellent adherence at follow-up. It is important to note that, while previous studies suggested that older age was associated with cognitive dysfunction that might result in poor adherence rate (Cherner et al., 2004; Chesney et al., 2000; Hardy et al., 1999) , the mean age of the participants in the present study were under 50s and age-related declines in cognition do not typically start at that age. In fact, older age and its association with better adherence have been documented in recent literature (Barclay et al., 2007; Hinkin et al., 2002; Hinkin et al., 2004; Solomon & Halkitis, 2008) . As excellent adherence rate would require strict adherence to dietary, dosage, and time restrictions, participants at older age may need less alternation in their daily activities or lifestyles to accommodate to such restrictions or find alternations in lifestyle less troublesome. Therefore, they may be more able to follow the instructions and be more likely to show excellent adherence to medication.
Participants who had excellent adherence also showed high level of self-efficacy with regard to adherence to medication. It is conceivable that patients who believed that they could follow the medication regimen would report excellent adherence rate (Barclay et al., 2007; Molassiotis et al., 2002; Wolf et al., 2007) . The result suggests that interventions should not just focus on practicing adherence behaviours, it is also important to increase their belief in their ability to follow the medication regimens (Battaglioli-DeNero, 2007; Chesney et al., 2000) .
Factors associated with unintentional non-adherence
In the present study, participants with longer length of diagnosis and started medication longer at baseline were more likely to be classified as unintentional nonadherers at follow-up. This is consistent with studies suggesting that adherence rate among patients decrease over time (Barclay et al., 2004; Deschamps et al., 2004; Mannheimer, Friedland, Matts, Child, & Chesney, 2002) . One possible explanation may be the gradual decrease in motivation in adhering to the medication. It can also be assumed that the longer one is diagnosed and on medications, the more likely that they will experience lifestyle disruptions that inevitably affect their medication taking.
Factors associated with intentional non-adherence Participants who were classified as intentional nonadherers had significantly poorer mental health, higher level of self-stigma, and reported higher use of avoidant coping strategies at baseline. Participants with poorer mental health might have poor access to health care, or have less ability in integrating complex medication regimens into their daily activities Tucker et al., 2004) . In addition, while taking medication in the public may signify a person's serostatus , individuals with high level of stigma may skip their medication to avoid disclosure of serostatus (Edwards, 2006; Ware et al., 2006) . The finding that avoidant coping is associated with intentional non-adherence is in line with previous literature (Halkitis, Parsons, Wolitski, & Remien, 2003; Singh et al., 1999; Weaver et al., 2005) . Individuals who use avoidant coping strategies may choose to escape the stressors when dealing with the disease and therefore, be less likely to take an active role in their medication management. In contrast, the use of approach coping (problem-focused and emotion-focused coping) strategies was not related to adherence. This suggests that minimizing the use of avoidant coping strategies should be prioritized in improving antiretroviral adherence rate.
Participants with more severe physical symptoms at baseline were more likely to be intentional nonadherers when compared with adherers. Result is consistent with previous study that physical symptoms were related to poorer adherence (Ammassari et al., 2001; Gonzalez et al., 2007; Holzemer et al., 1999) . Since avoiding side effects represented a factor of intentional non-adherence, it could be conjectured that participants might discontinue their medication to minimize the severity of symptoms. It would also be possible that physical limitations caused by symptoms made participants difficult in following the medication regimen.
Limitations of the study Antiretroviral adherence was assessed using selfreport measure in the present study. There has been discussion that self-report assessment might underestimate the non-adherence rate compared to other objective measures, such as pill counts, Medication Events Monitoring System (MEMS), pharmacist report, or biological markers (Chesney et al., 1999; Samet et al., 2001) . Future studies should seek to assess adherence rate using multiple measures (Hill et al., 2003) . In addition, non-adherence in the present study was defined by a new set of more extensive, arbitrary criteria. Although this is believed to be a more comprehensive measure for non-adherence, more studies are needed to test the validity of this new measure. Nevertheless, it is important to point out that a similar approach of measuring nonadherence was employed by recent study (Reynolds et al., 2007) and was proved to be reliable.
Implications and conclusions
Results of the present study highlight the need for a more comprehensive measurement of antiretroviral adherence, and the importance of distinguishing the reasons behind intentions for non-adherence and targeting different variables for patients who may not adhere to medication due to different reasons. To minimize intentional non-adherence, intervention should target on symptom control, improving patients' mental health, stigma reduction, and reducing the use of avoidant coping strategies. Education is also warranted to remind adherence among patients with longer length of diagnosis and medication history to minimize unintentional non-adherence. To promote adherence behaviour, improving selfefficacy in medication taking would be particularly vital. Individualized assessment and tailored education would be important to remove the specific barriers to adherence and to increase general antiretroviral adherence rates.
